Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + S-1 + intravenous/intraperitoneal paclitaxel for gastric cancer with peritoneal metastasis
ChiCTR2100052478Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, tegafur and paclitaxel in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Shandong Cancer Hospital. Primary endpoints: R0 resection rate and Conversion rate of operation. Started Oct 2021; status: recruiting.
02
Drugs
sintilimabtegafurpaclitaxel
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100052478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052478.